Philips Achieves Top Spot in European Patent Filings for Medical Technology
Amsterdam, the Netherlands – March 25, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a prominent name in health technology worldwide, announced today that it led the field of medical technology patent applications at the European Patent Office (EPO) in 2024. The company filed 594 Medtech patent applications, reinforcing its commitment to transforming healthcare through the integration of informatics and AI.
Philips’ innovations, built on 134 years of research and development, improved the lives of nearly 2 billion people in 2024, according to the company. This puts them on track to reach their 2030 goal of improving the lives of 2.5 billion people.
Roy Jakobs, CEO of Royal Philips, stated, “For over a century, Philips has been at the forefront of innovations that improve people’s lives. The 2024 European patent rankings demonstrate our ongoing innovation in hospitals and homes, helping to deliver better care for more people. To further amplify this impact, we have shifted our innovation efforts closer to our customers to help healthcare professionals improve patient care and empower individuals to manage their health and well-being.”
With informatics and AI rapidly increasing in value for healthcare applications both in hospitals and at home, Philips allocates approximately half of its research and development investments to these technologies. Some of the informatics- and AI-powered innovations launched by Philips in 2024 include:
- The new Azurion image-guided therapy system with advanced informatics for enhanced minimally invasive diagnosis and treatment of stroke and other neurovascular patients.
- FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound systems to improve cardiovascular imaging, enhance automation, and boost productivity, solidifying Philips’ global leadership in cardiovascular ultrasound.
- The new Philips Spectral CT 7500 RT, which enables personalized radiation therapy planning to improve care for an increased number of cancer patients.
- FDA approval for the LumiGuide Navigation Wire, utilizing fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery.
In total, Philips submitted 1,231 European patent applications across various domains, more than any other Dutch company. This maintains its position as one of the top applicants since the EPO began publishing rankings in 2004.
Further demonstrating Philips’ leadership in innovation, the company has been included in the Clarivate Top 100 Global Innovators 2025, marking its 12th consecutive year in this important assessment of global innovators.
Philips invested approximately EUR 1.7 billion in research and development in 2024, supporting its goal of improving care for more people. This represents over 9% of its sales, significantly above the industry average. The company’s extensive intellectual property portfolio includes 50,500 patent rights, 30,500 trademarks, 150,000 design rights, and 3,200 domain names.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company dedicated to enhancing people’s health and well-being through meaningful innovation. Philips’ people- and patient-centric approach leverages advanced technology and in-depth clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in both hospitals and at home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated EUR 18 billion in sales in 2024 and employs roughly 67,800 employees with sales and services in over 100 countries. News about Philips can be found at www.philips.com/newscenter.
Contact
Elco van Groningen Philips Global External Relations Tel.: +31 6 8103 9584 E-mail: media@philips.com
